Skip to content
SPACListing
Browse
ScreenerFilingsMarketDeadlinesSponsorsBanksSectorsLearnPricingWatchlist
SearchingNYSE

Jackson Acquisition Co IIJACS

Class A JACSUnits JACS-UNCIK 0002039058

Cash in trust

$246.8M

$246,845,170

Trust per share

Redemption value

IPO

Dec 2024

Combination deadline

Dec 11, 2026

98 days remaining

Filings on record

66

Latest Aug 14, 2026

Overview

Jackson Acquisition Co II is a special purpose acquisition company incorporated and registered with the SEC under CIK 0002039058. It completed its initial public offering in Dec 2024 and listing on NYSE. Class A shares trade under the ticker JACS, units under JACS-UN on NYSE. The vehicle is sponsored by RJ Healthcare through RJ Healthcare SPAC II, LLC. The mandate targets technology, healthcare. IPO closed, trust funded, no definitive agreement announced.

we intend to focus our search for a target business by concentrating our efforts in identifying high -quality businesses with a focus on healthcare services, healthcare technology, or otherwise focused on the healthcare industry.
The mandate, as stated in the IPO prospectus

Reading the filings

Arithmetic on what Jackson Acquisition Co II has disclosed, written the way a desk would read it. These are observations, not a rating. Nothing here scores the vehicle or implies a view on it.

  • Time on the clock

    98 days to the Dec 11, 2026 deadline. Still workable for a deal already in diligence, tight for one that has not been found. Watch for an extension proxy, which typically appears a month or two before the date.

  • Sponsor record

    RJ Healthcare has launched 2 vehicles. Of the 1 that have resolved, 0 closed a combination and 1 liquidated, a 0% completion rate. A sponsor's record is not a forecast, but it does tell you whether the team has taken a deal across the line before.

Scores

Recomputed 4m ago

Three readings of Jackson Acquisition Co II, each an unweighted mean of the components shown beneath it, and each component a percentile against every live SPAC rather than an absolute we invented. They describe the setup, not the merit. How they are built

Edge

Low

How much does the structure protect a holder right now?

25/100

  • Runway17

    98 days

  • Sponsor record33

    0.0%

Edge reads the setup, not the business. A vehicle can score well on protection and still be a poor place to leave money once a deal closes.

FOMO

Low

How much attention is this vehicle attracting right now?

19/100

  • Filing activity38

    2 in 30 days

  • News coverage0

    0 stories in 30 days

Attention is not quality. FOMO rises on news volume and on the market paying above trust, both of which have preceded plenty of disappointments.

Potential

Moderate

How likely is this vehicle to complete a combination, and at what scale?

48/100

  • Sponsor record33

    0.0%

  • Trust scale71

    $247M

  • Stage40

    searching

Potential is about execution, not about the target. It says nothing about whether the eventual deal is worth owning, because the target is usually unknown when the score is computed.

These are derived measures, not ratings of investment merit. They carry no view on the target, no price target and no recommendation, and a high score is not a reason to buy anything.

SEC filing history

Free tier: filings older than 24 hours
  • SCHEDULE 13G/A

    Amended beneficial ownership report (passive)

    Accession 0001905106-26-000160

    Aug 14, 2026

    21d ago

    Open filing
  • 10-Q

    Quarterly report

    Accession 0001213900-26-087786

    Aug 11, 2026

    23d ago

    Open filing
  • SCHEDULE 13G

    Beneficial ownership report (passive)

    Accession 0001905106-26-000091

    May 15, 2026

    3mo ago

    Open filing
  • 10-Q

    Quarterly report

    Accession 0001213900-26-056121

    May 14, 2026

    3mo ago

    Open filing
  • SCHEDULE 13G/A

    Amended beneficial ownership report (passive)

    Accession 0001167557-26-000054

    May 12, 2026

    3mo ago

    Open filing
  • SCHEDULE 13G/A

    Amended beneficial ownership report (passive)

    Accession 0000886982-26-000196

    May 11, 2026

    3mo ago

    Open filing
  • 10-K

    Annual report

    Accession 0001213900-26-032353

    Mar 20, 2026

    5mo ago

    Open filing
  • SCHEDULE 13G

    Beneficial ownership report (passive)

    Accession 0001062993-26-000981

    Feb 17, 2026

    6mo ago

    Open filing
  • SCHEDULE 13G/A

    Amended beneficial ownership report (passive)

    Accession 0000927971-26-000016

    Feb 12, 2026

    6mo ago

    Open filing
  • 8-K

    Notice of delisting or failure to satisfy a listing rule

    Items 3.01, 9.01 · Accession 0001213900-26-014277

    Feb 10, 2026

    6mo ago

    Open filing
  • SCHEDULE 13G/A

    Amended beneficial ownership report (passive)

    Accession 0001905106-25-000070

    Nov 14, 2025

    9mo ago

    Open filing
  • SCHEDULE 13G/A

    Amended beneficial ownership report (passive)

    Accession 0000886982-25-001502

    Nov 14, 2025

    9mo ago

    Open filing
  • SCHEDULE 13G/A

    Amended beneficial ownership report (passive)

    Accession 0000312069-25-000579

    Nov 12, 2025

    9mo ago

    Open filing
  • 10-Q

    Quarterly report

    Accession 0001213900-25-107171

    Nov 6, 2025

    10mo ago

    Open filing
  • SCHEDULE 13G/A

    Amended beneficial ownership report (passive)

    Accession 0001326389-25-000270

    Aug 14, 2025

    1y ago

    Open filing
  • SCHEDULE 13G

    Beneficial ownership report (passive)

    Accession 0001076809-25-000091

    Aug 14, 2025

    1y ago

    Open filing
  • SCHEDULE 13G

    Beneficial ownership report (passive)

    Accession 0001905106-25-000030

    Aug 14, 2025

    1y ago

    Open filing
  • SCHEDULE 13G/A

    Amended beneficial ownership report (passive)

    Accession 0000950170-25-108459

    Aug 14, 2025

    1y ago

    Open filing
  • 10-Q

    Quarterly report

    Accession 0001213900-25-073677

    Aug 8, 2025

    1y ago

    Open filing
  • SCHEDULE 13G

    Beneficial ownership report (passive)

    Accession 0001393825-25-000050

    Aug 8, 2025

    1y ago

    Open filing
  • SCHEDULE 13G/A

    Amended beneficial ownership report (passive)

    Accession 0001085146-25-004396

    Jul 31, 2025

    1y ago

    Open filing
  • SCHEDULE 13G/A

    Amended beneficial ownership report (passive)

    Accession 0000950170-25-072261

    May 15, 2025

    1y ago

    Open filing
  • SCHEDULE 13G/A

    Amended beneficial ownership report (passive)

    Accession 0001085146-25-003118

    May 14, 2025

    1y ago

    Open filing
  • SCHEDULE 13G

    Beneficial ownership report (passive)

    Accession 0000312069-25-000395

    May 13, 2025

    1y ago

    Open filing
  • SCHEDULE 13G

    Beneficial ownership report (passive)

    Accession 0000769993-25-000285

    May 13, 2025

    1y ago

    Open filing
  • 10-Q

    Quarterly report

    Accession 0001213900-25-041127

    May 8, 2025

    1y ago

    Open filing
  • SCHEDULE 13G/A

    Amended beneficial ownership report (passive)

    Accession 0001085146-25-002810

    May 8, 2025

    1y ago

    Open filing
  • SCHEDULE 13G

    Beneficial ownership report (passive)

    Accession 0001085146-25-002795

    May 8, 2025

    1y ago

    Open filing
  • 10-K

    Annual report

    Accession 0001013762-25-000620

    Mar 18, 2025

    1y ago

    Open filing
  • SCHEDULE 13G

    Beneficial ownership report (passive)

    Accession 0001326389-25-000134

    Feb 14, 2025

    1y ago

    Open filing

Jackson Acquisition Co II: questions answered

What is Jackson Acquisition Co II (JACS)?

Jackson Acquisition Co II is a special purpose acquisition company incorporated and registered with the SEC under CIK 0002039058. It completed its initial public offering in Dec 2024 and listing on NYSE. Class A shares trade under the ticker JACS, units under JACS-UN on NYSE. The vehicle is sponsored by RJ Healthcare through RJ Healthcare SPAC II, LLC. The mandate targets technology, healthcare. IPO closed, trust funded, no definitive agreement announced.

How much does Jackson Acquisition Co II hold in trust?

Approximately $246,845,170, as at the most recent filing on record. Trust balances move: shareholders redeem at extension votes and at the combination vote, and sponsors pay contributions in to extend. Treat the figure as a point-in-time disclosure, not a running balance.

When must Jackson Acquisition Co II complete a merger?

By Dec 11, 2026. If no combination closes by then the sponsor must seek a further extension or wind the vehicle up and return the trust.

What happens if Jackson Acquisition Co II does not find a target in time?

The charter requires the vehicle to redeem 100% of the public shares and return the trust, pro rata, to public shareholders. That is the mechanism working as designed rather than a default. Founder shares and warrants are worthless in that outcome, which is why the sponsor's incentive is to get a deal done or to buy more time. Across the market, deadline lapsed without a deal; trust returned to public shareholders.

Can I redeem shares in Jackson Acquisition Co II, and at what price?

Public shareholders may elect to redeem in connection with a combination vote and at each extension vote, at the pro-rata trust value on the relevant record date. Redemption is a right attached to the public shares only; warrants and rights carry no claim on the trust. The mechanics and the deadline for electing are set out in the proxy statement for the vote in question.

What tickers does Jackson Acquisition Co II trade under?

Class A shares trade as JACS on NYSE, the units as JACS-UN. Units trade first and separate into their component securities roughly 52 days after the IPO; only the Class A shares carry the redemption right against the trust.

Is the trust value the same as the share price for Jackson Acquisition Co II?

No. Trust per share is a disclosed, contractual figure: what a redeeming holder receives. The market price is whatever the shares change hands at, which can sit above the trust when a deal is well received or below it when the market doubts one will close. We do not have a current quote for this vehicle, so no spread is shown.

How much dilution do Jackson Acquisition Co II's founder shares and warrants create?

Both are disclosed in the prospectus and both survive into the combined company, which is why a de-SPAC at $10 is not economically the same as an IPO at $10.

Who sponsors Jackson Acquisition Co II, and what is their track record?

RJ Healthcare SPAC II, LLC is the sponsor entity, part of the RJ Healthcare franchise. That franchise has launched 2 vehicles in total, of which 0 closed a combination and 1 liquidated, a 0% completion rate on resolved vehicles. Named principals: Richard L. Jackson.

Is Jackson Acquisition Co II tradeable, and where?

Yes. JACS returned a live quote of $10.73 on NYSE. Quotes here are delayed and refreshed on a schedule rather than streamed, so treat the figure as indicative and confirm on your own venue. Units and warrants trade under their own symbols and are quoted separately.

Is Jackson Acquisition Co II a good investment?

That is not a question this site answers. Jackson Acquisition Co II is covered here as reference data: what the company filed, when it filed it, and what the numbers in those filings say. The Edge, FOMO and Potential scores on this page are derived measures with a published formula, not ratings of investment merit: they describe the setup, and every component is shown so you can take them apart. We publish no price targets and no recommendations, and nothing here should be read as advice. The figures are a starting point for your own work, and each one carries the accession number of the filing it came from.

Where does this Jackson Acquisition Co II data come from?

Filings Jackson Acquisition Co II submitted to the SEC under CIK 0002039058: the registration statement and final prospectus for the structure, quarterly and annual reports for the trust, current reports and proxy statements for deals, votes and extensions. Trust economics are taken from the registrant's own XBRL tags rather than parsed from prose, which is why they are exact. Every filing in the history above is listed with its accession number, which identifies the document uniquely on EDGAR; Pro accounts open it directly from the row.

Compiled by the SPACListing research desk

Last reconciled Sep 4, 2026

Every figure on this page is read from documents the registrants filed with the U.S. Securities and Exchange Commission, principally the IPO prospectus (Form 424B4), quarterly and annual reports, current reports and proxy statements, the registrant's own XBRL tags for trust economics. Nothing is sourced from press coverage, from the companies themselves, or from a third-party aggregator. Where a filing does not disclose something, the field is left blank rather than estimated.

Read the full methodology · What is in the dataset · Report a correction

SPACListing is a reference-data service, not an investment adviser. Nothing here is a recommendation to buy or sell any security.

Continue reading

The context around this vehicle: who else the sponsor has launched, which banks priced it, and where it sits in the wider market.